{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:19:30Z","timestamp":1792628370883,"version":"4.5.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Inhibitors of the sodium-glucose cotransporter 2 (SGLT2i) were originally developed to treat diabetes mellitus but have shown important renoprotective benefits independently from blood glucose levels. SGLT2i have thus become an important addition to the therapeutic armamentarium to treat patients with chronic kidney disease. However, specific patient populations were excluded from the pivotal trials, for instance patients with very low eGFR, patients on dialysis, kidney transplant recipients, and patients with autosomal dominant polycystic kidney disease (ADPKD), the most common genetic kidney disorder. Considering the lack of potent treatment modalities in ADPKD, the use of SGLT2i in this patient population would be of major interest. However, the combination of inconclusive results from preclinical models with the lack of clinical efficacy data and potential disease-specific safety concerns currently exclude patients with ADPKD from this promising therapeutic opportunity. This results in an urgent need for adequately powered clinical trials examining SGLT2i in ADPKD. This review summarizes the current knowledge on SGLT2i in this specific patient population and outlines running and upcoming clinical trial programs in different geographic regions aiming to make SGLT2i accessible to patients with ADPKD.<\/jats:p>","DOI":"10.1093\/ndt\/gfaf061","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T18:53:24Z","timestamp":1744052004000},"page":"2231-2238","source":"Crossref","is-referenced-by-count":29,"title":["SGLT2 inhibition for patients with ADPKD \u2013 closing the evidence gap"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6910-0745","authenticated-orcid":false,"given":"Roman-Ulrich","family":"M\u00fcller","sequence":"first","affiliation":[{"name":"Faculty of Medicine and University Hospital, University of Cologne Department II of Internal Medicine, , Cologne ,","place":["Germany"]},{"name":"Center for Rare Diseases Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne , Cologne ,","place":["Germany"]},{"name":"Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5953-5785","authenticated-orcid":false,"given":"Dominique","family":"Guerrot","sequence":"additional","affiliation":[{"name":"Univ. Rouen Normandie, INSERM EnVI U1096, CHU Rouen , CIC-CRB 1404, Department of Nephrology, Rouen ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Chonchol","sequence":"additional","affiliation":[{"name":"Division of Nephrology , Department of Medicine University of Colorado-Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Hannover Medical School Department of Nephrology and Hypertension, , Hannover ,","place":["Germany"]},{"name":"University Hospital Schleswig Holstein Department of Nephrology and Hypertension, , Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"International University of Health and Welfare Narita Hospital Department of Nephrology, , Chiba ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T","family":"Gansevoort","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, University of Groningen Department Nephrology, , Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1958-4459","authenticated-orcid":false,"given":"Emilie","family":"Cornec-Le Gall","sequence":"additional","affiliation":[{"name":"University of Brest, Inserm, Unit\u00e9 Mixte de Recherche 1078, G\u00e9n\u00e9tique, G\u00e9nomique fonctionnelle et Biotechnologies, Centre Hospitalier Universitaire Brest, Centre de R\u00e9f\u00e9rences Maladies R\u00e9nales H\u00e9r\u00e9ditaires de l'Adulte et de l'Enfant MARHEA , Brest ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"2025112604015628300_bib1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2025112604015628300_bib2","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"Thomson","year":"2012","journal-title":"Am J Physiol-Regul Integr Comp Physiol"},{"key":"2025112604015628300_bib3","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors","volume":"75","author":"Cs","year":"2020","journal-title":"Hypertension"},{"key":"2025112604015628300_bib4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"2025112604015628300_bib5","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet"},{"key":"2025112604015628300_bib6","doi-asserted-by":"publisher","first-page":"F1041","DOI":"10.1152\/ajprenal.00005.2024","article-title":"SGLT2-independent effects of canagliflozin on NHE3 and mitochondrial complex I activity inhibit proximal tubule fluid transport and albumin uptake","volume":"326","author":"Albalawy","year":"2024","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025112604015628300_bib7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jdi.12851","article-title":"Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: The Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study","volume":"10","author":"Sasaki","year":"2019","journal-title":"J Diabetes Invest"},{"key":"2025112604015628300_bib8","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"2025112604015628300_bib9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12933-021-01312-8","article-title":"Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGF\u03b21\/Smad signaling","volume":"20","author":"Zhang","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2025112604015628300_bib10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor \u03b1-stimulated human coronary arterial endothelial cells","volume":"53","author":"Uthman","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"2025112604015628300_bib11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4070\/kcj.2020.0303","article-title":"Sodium\/glucose co-transporter 2 inhibitor, empagliflozin, alleviated transient expression of SGLT2 after myocardial infarction","volume":"51","author":"Lee","year":"2021","journal-title":"Korean Circ J"},{"key":"2025112604015628300_bib12","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2025112604015628300_bib13","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2025112604015628300_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2025112604015628300_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2213-8587(23)00321-2","article-title":"Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-Kidney trial","volume":"12","author":"Staplin","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025112604015628300_bib16","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2025112604015628300_bib17","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","article-title":"Kidney and heart failure outcomes associated with SGLT2 inhibitor use","volume":"18","author":"van der Aart-van der Beek","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"2025112604015628300_bib18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1536\/ihj.22-441","article-title":"Safety of SGLT2 inhibitors in three chronic diseases","volume":"64","author":"Ge","year":"2023","journal-title":"Int Heart J"},{"key":"2025112604015628300_bib19","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/ckj\/sfac029","article-title":"Sodium\u2013glucose cotransporter inhibition in polycystic kidney disease: fact or fiction","volume":"15","author":"Afsar","year":"2022","journal-title":"Clin Kidney J"},{"key":"2025112604015628300_bib20","doi-asserted-by":"publisher","first-page":"724","DOI":"10.34067\/KID.0000000000000412","article-title":"Renal hemodynamic and functional changes in patients with ADPKD","volume":"5","author":"Ishii","year":"2024","journal-title":"Kidney360"},{"key":"2025112604015628300_bib21","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.2215\/CJN.00360110","article-title":"Early renal abnormalities in autosomal dominant polycystic kidney disease","volume":"5","author":"Meijer","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025112604015628300_bib22","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1681\/ASN.V561349","article-title":"Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease","volume":"5","author":"Chapman","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"2025112604015628300_bib23","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1681\/ASN.V9101908","article-title":"Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease","volume":"9","author":"Sharp","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"2025112604015628300_bib24","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/ndt\/gfv422","article-title":"Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dialysis Transplant"},{"key":"2025112604015628300_bib25","doi-asserted-by":"crossref","first-page":"101283","DOI":"10.1016\/j.xcrm.2023.101283","article-title":"Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD\u2014a randomized controlled trial","volume":"4","author":"Cukoski","year":"2023","journal-title":"Cell Rep Med"},{"key":"2025112604015628300_bib26","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/ndt\/gfac311","article-title":"RESET-PKD: A pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease","volume":"38","author":"Oehm","year":"2023","journal-title":"Nephrol Dialysis Transplant"},{"key":"2025112604015628300_bib27","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/ndt\/gfad239","article-title":"Higher beta-hydroxybutyrate ketone levels associated with a slower kidney function decline in ADPKD","volume":"39","author":"Knol","year":"2024","journal-title":"Nephrol Dialysis Transplant"},{"key":"2025112604015628300_bib28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2025112604015628300_bib29","doi-asserted-by":"publisher","first-page":"103697","DOI":"10.1016\/j.isci.2021.103697","article-title":"Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease","volume":"25","author":"Hopp","year":"2022","journal-title":"iScience"},{"key":"2025112604015628300_bib30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.7570\/jomes21061","article-title":"Effect of Sodium-glucose cotransporter 2 inhibitors on weight reduction in overweight and obese populations without diabetes: a systematic review and a meta-analysis","volume":"30","author":"Cho","year":"2021","journal-title":"J Obes Metabol Synd"},{"key":"2025112604015628300_bib31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jamainternmed.2023.7660","article-title":"Sodium-glucose cotransporter 2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes","volume":"184","author":"Paik","year":"2024","journal-title":"JAMA Intern Med."},{"key":"2025112604015628300_bib32","doi-asserted-by":"publisher","first-page":"e059073","DOI":"10.1136\/bmjopen-2021-059073","article-title":"Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial","volume":"12","author":"Schietzel","year":"2022","journal-title":"BMJ Open"},{"key":"2025112604015628300_bib33","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2025112604015628300_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/JCI128503","article-title":"Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease","volume":"129","author":"Torres","year":"2019","journal-title":"J Clin Invest"},{"key":"2025112604015628300_bib35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2025112604015628300_bib36","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"2025112604015628300_bib37","doi-asserted-by":"publisher","first-page":"e14360","DOI":"10.14814\/phy2.14360","article-title":"Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume","volume":"8","author":"Masuda","year":"2020","journal-title":"Physiol Rep"},{"key":"2025112604015628300_bib38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.diabet.2019.11.006","article-title":"SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes","volume":"46","author":"Lytvyn","year":"2020","journal-title":"Diabetes Metab"},{"key":"2025112604015628300_bib39","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/dom.14729","article-title":"Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: results from DAPASALT and DIAMOND","volume":"24","author":"Sen","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2025112604015628300_bib40","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","article-title":"Water conservation overrides osmotic diuresis during SGLT2 inhibition in patients with heart failure","volume":"83","author":"Marton","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025112604015628300_bib41","doi-asserted-by":"publisher","first-page":"13815","DOI":"10.1038\/s41598-021-93296-4","article-title":"High glucose induces trafficking of prorenin receptor and stimulates profibrotic factors in the collecting duct","volume":"11","author":"Gogulamudi","year":"2021","journal-title":"Sci Rep"},{"key":"2025112604015628300_bib42","doi-asserted-by":"publisher","first-page":"1118358","DOI":"10.3389\/fphar.2023.1118358","article-title":"Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct","volume":"14","author":"Sinha","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025112604015628300_bib43","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.199","article-title":"Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats","volume":"84","author":"Wang","year":"2013","journal-title":"Kidney Int"},{"key":"2025112604015628300_bib44","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1159\/000368540","article-title":"Inhibition of sodium-glucose cotransporter 2 with dapagliflozin in Han: SPRD rats with polycystic kidney disease","volume":"40","author":"Rodriguez","year":"2015","journal-title":"Kidney Blood Press Res"},{"key":"2025112604015628300_bib45","doi-asserted-by":"publisher","first-page":"e0125603","DOI":"10.1371\/journal.pone.0125603","article-title":"Effect of sodium-glucose cotransport inhibition on polycystic kidney disease progression in PCK rats","volume":"10","author":"Kapoor","year":"2015","journal-title":"PLoS ONE"},{"key":"2025112604015628300_bib46","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ebiom.2019.08.041","article-title":"Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease","volume":"47","author":"Leonhard","year":"2019","journal-title":"EBioMedicine"},{"key":"2025112604015628300_bib47","doi-asserted-by":"publisher","first-page":"7918","DOI":"10.1038\/s41467-022-35537-2","article-title":"Glucose absorption drives cystogenesis in a human organoid-on-chip model of polycystic kidney disease","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"2025112604015628300_bib48","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s13730-024-00859-1","article-title":"Additional renoprotective effect of the SGLT2 inhibitor dapagliflozin in a patient with ADPKD receiving tolvaptan treatment","volume":"13","author":"Minatoguchi","year":"2024","journal-title":"CEN Case Rep"},{"key":"2025112604015628300_bib49","doi-asserted-by":"publisher","first-page":"sfae186","DOI":"10.1093\/ckj\/sfae186","article-title":"Dapagliflozin treatment in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease","volume":"17","author":"Yoshimoto","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025112604015628300_bib50","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s13730-023-00840-4","article-title":"Dapagliflozin administration for 1 year promoted kidney enlargement in patient with ADPKD","volume":"13","author":"Nakatani","year":"2024","journal-title":"CEN Case Rep"},{"key":"2025112604015628300_bib51","doi-asserted-by":"publisher","first-page":"6341","DOI":"10.3390\/jcm12196341","article-title":"Short-term dapagliflozin administration in autosomal dominant polycystic kidney disease-a retrospective single-arm case series study","volume":"12","author":"Morioka","year":"2023","journal-title":"JCM"},{"key":"2025112604015628300_bib52","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2024.07.009","article-title":"KDIGO 2025 Clinical Practice Guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD)","volume":"107","author":"Kidney Disease: Improving Global Outcomes (KDIGO) ADPKD Work Group","year":"2025","journal-title":"Kidney Int"},{"key":"2025112604015628300_bib53","doi-asserted-by":"publisher","first-page":"e088317","DOI":"10.1136\/bmjopen-2024-088317","article-title":"Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial","volume":"14","author":"Bahlmann-Kroll","year":"2024","journal-title":"BMJ Open"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf061\/62892575\/gfaf061.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/12\/2231\/62892575\/gfaf061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/12\/2231\/62892575\/gfaf061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T09:02:05Z","timestamp":1764147725000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/12\/2231\/8108808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,4,8]]},"published-print":{"date-parts":[[2025,11,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf061","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,4,8]]}}}